Glial fibrillary acidic protein as a marker of astrocytic activation in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis

Felix Benninger; Micaela J. Glat; Daniel Offen; Israel Steiner

doi:https://doi.org/10.1016/j.jocn.2015.10.008

Glial fibrillary acidic protein as a marker of astrocytic activation in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis

Felix Benninger, Micaela J. Glat, Daniel Offen, Israel Steiner

Tel Aviv University

Research output: Contribution to journal › Article › peer-review

Abstract

Glial fibrillary acidic protein (GFAP) has been shown to be increased in the cerebrospinal fluid (CSF) of patients suffering from neurological diseases involving the activation of astrocytes, but has not been studied in amyotrophic lateral sclerosis (ALS) patients to our knowledge. CSF samples of patients with definite ALS and of those with other neurological diseases were evaluated for their GFAP concentrations. CSF-GFAP concentrations of patients with ALS were significantly elevated by 53% compared to patients with other neurologic diseases. GFAP might serve as a biomarker in ALS. Our findings support the concept that astrocytes play a role in ALS pathogenesis.

Original language	English
Pages (from-to)	75-78
Number of pages	4
Journal	Journal of Clinical Neuroscience
Volume	26
DOIs	https://doi.org/10.1016/j.jocn.2015.10.008
State	Published - 1 Apr 2016

Keywords

Amyotrophic lateral sclerosis
Astrocytes
Biomarker
GFAP
Motor neuron disease

All Science Journal Classification (ASJC) codes

Surgery
Neurology
Clinical Neurology
Physiology (medical)

Access to Document

https://doi.org/10.1016/j.jocn.2015.10.008

Cite this

@article{12bfdff7b3cf4fd9a6218c72ff457be2,

title = "Glial fibrillary acidic protein as a marker of astrocytic activation in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis",

abstract = "Glial fibrillary acidic protein (GFAP) has been shown to be increased in the cerebrospinal fluid (CSF) of patients suffering from neurological diseases involving the activation of astrocytes, but has not been studied in amyotrophic lateral sclerosis (ALS) patients to our knowledge. CSF samples of patients with definite ALS and of those with other neurological diseases were evaluated for their GFAP concentrations. CSF-GFAP concentrations of patients with ALS were significantly elevated by 53% compared to patients with other neurologic diseases. GFAP might serve as a biomarker in ALS. Our findings support the concept that astrocytes play a role in ALS pathogenesis.",

keywords = "Amyotrophic lateral sclerosis, Astrocytes, Biomarker, GFAP, Motor neuron disease",

author = "Felix Benninger and Glat, {Micaela J.} and Daniel Offen and Israel Steiner",

year = "2016",

month = apr,

day = "1",

doi = "https://doi.org/10.1016/j.jocn.2015.10.008",

language = "الإنجليزيّة",

volume = "26",

pages = "75--78",

journal = "Journal of Clinical Neuroscience",

issn = "0967-5868",

publisher = "Churchill Livingstone",

}

TY - JOUR

T1 - Glial fibrillary acidic protein as a marker of astrocytic activation in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis

AU - Benninger, Felix

AU - Glat, Micaela J.

AU - Offen, Daniel

AU - Steiner, Israel

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Glial fibrillary acidic protein (GFAP) has been shown to be increased in the cerebrospinal fluid (CSF) of patients suffering from neurological diseases involving the activation of astrocytes, but has not been studied in amyotrophic lateral sclerosis (ALS) patients to our knowledge. CSF samples of patients with definite ALS and of those with other neurological diseases were evaluated for their GFAP concentrations. CSF-GFAP concentrations of patients with ALS were significantly elevated by 53% compared to patients with other neurologic diseases. GFAP might serve as a biomarker in ALS. Our findings support the concept that astrocytes play a role in ALS pathogenesis.

AB - Glial fibrillary acidic protein (GFAP) has been shown to be increased in the cerebrospinal fluid (CSF) of patients suffering from neurological diseases involving the activation of astrocytes, but has not been studied in amyotrophic lateral sclerosis (ALS) patients to our knowledge. CSF samples of patients with definite ALS and of those with other neurological diseases were evaluated for their GFAP concentrations. CSF-GFAP concentrations of patients with ALS were significantly elevated by 53% compared to patients with other neurologic diseases. GFAP might serve as a biomarker in ALS. Our findings support the concept that astrocytes play a role in ALS pathogenesis.

KW - Amyotrophic lateral sclerosis

KW - Astrocytes

KW - Biomarker

KW - GFAP

KW - Motor neuron disease

UR - http://www.scopus.com/inward/record.url?scp=84947333002&partnerID=8YFLogxK

U2 - https://doi.org/10.1016/j.jocn.2015.10.008

DO - https://doi.org/10.1016/j.jocn.2015.10.008

M3 - مقالة

C2 - 26602604

SN - 0967-5868

VL - 26

SP - 75

EP - 78

JO - Journal of Clinical Neuroscience

JF - Journal of Clinical Neuroscience

ER -

Glial fibrillary acidic protein as a marker of astrocytic activation in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis

Abstract

Keywords

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this